Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25132248 | 0.74 | CA1 (0.37) | CA1CA2CA4KMT2APTGS1 | |
| SCHEMBL28441454 | 0.74 | CA1 (0.41) | CA1CA2CA4CYP2D6KMT2A | |
| SCHEMBL18611293 | 0.74 | CA1 (0.41) | CA1CA2CA4CYP2D6KMT2A | |
| SCHEMBL18611286 | 0.74 | CA1 (0.41) | CA1CA2CA4CYP2D6KMT2A | |
| SCHEMBL18611288 | 0.74 | CA1 (0.41) | CA1CA2CA4KMT2A | |
| SCHEMBL22772431 | 0.74 | CA1 (0.41) | CA1CA2CA4KMT2A | |
| SCHEMBL22462732 | 0.74 | TDP1 (0.37) | CA1CA2CA4KMT2A | |
| SCHEMBL11803340 | 0.72 | CA1 (0.35) | CA1CA2CA4KMT2A | |
| SCHEMBL14763899 | 0.72 | CA1 (0.35) | CA1CA2CA4KMT2A | |
| SCHEMBL21160588 | 0.72 | PTGS1 (0.35) | CYP2D6KMT2APTGS1PTGS2OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| US-11679109-B2 | SMARCA degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2023-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240024318-A1 | SMARCA DEGRADERS AND USES THEREOF | SMARCA1, SMARCA2, SMARCC2 | CA1 3255/4885CA2 4080/4885CA4 2022/4885 |
| US-11679109-B2 | SMARCA degraders and uses thereof | SMARCA1, SMARCA2, SMARCC2 | CA1 3255/4885CA2 4080/4885CA4 2022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.